Atorvastatin 20 mg tablet
Public data on atorvastatin from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
NADAC per unit, monthly
ATORVASTATIN 20 MG TABLETShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2013-11 | 0.18271 |
| 2014-02 | 0.17329 |
| 2014-05 | 0.16323 |
| 2014-08 | 0.15537 |
| 2014-11 | 0.15354 |
| 2015-02 | 0.16369 |
| 2015-05 | 0.14956 |
| 2015-08 | 0.13452 |
| 2015-11 | 0.13106 |
| 2016-02 | 0.13578 |
| 2016-05 | 0.13270 |
| 2016-08 | 0.12728 |
| 2016-11 | 0.11949 |
| 2017-02 | 0.12039 |
| 2017-05 | 0.10969 |
| 2017-08 | 0.10284 |
| 2017-11 | 0.10358 |
| 2018-02 | 0.08286 |
| 2018-05 | 0.07700 |
| 2018-08 | 0.08128 |
| 2018-11 | 0.06909 |
| 2019-02 | 0.06987 |
| 2019-05 | 0.06784 |
| 2019-08 | 0.08458 |
| 2019-11 | 0.07900 |
| 2020-02 | 0.07667 |
| 2020-05 | 0.08072 |
| 2020-08 | 0.07171 |
| 2020-11 | 0.06418 |
| 2021-02 | 0.05761 |
| 2021-05 | 0.05566 |
| 2021-08 | 0.05571 |
| 2021-11 | 0.05515 |
| 2022-02 | 0.04616 |
| 2022-05 | 0.04533 |
| 2022-08 | 0.04748 |
| 2022-11 | 0.05144 |
| 2023-02 | 0.04449 |
| 2023-05 | 0.04094 |
| 2023-08 | 0.04069 |
| 2023-11 | 0.03755 |
| 2024-02 | 0.04093 |
| 2024-05 | 0.03394 |
| 2024-08 | 0.03497 |
| 2024-11 | 0.03168 |
| 2025-02 | 0.03289 |
| 2025-05 | 0.03455 |
| 2025-08 | 0.03448 |
| 2025-11 | 0.03097 |
| 2026-02 | 0.03002 |
| 2026-05 | 0.02887 |
| 2026-08 | 0.02778 |
| 2026-11 | 0.02858 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning atorvastatin
openFDA enforcement records, by year reported.
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 9 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 9 |
| 2017 | 6 |
| 2016 | 4 |
68 records since 2012. A record is one product or lot, not one recall event. Combination products that contain atorvastatin are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention atorvastatin
47 GxRadar articles cite or discuss this drug.
What pharmacies paid for atorvastatin, 2013 to 2026
Federal survey data show the pharmacy cost of a generic 20 mg atorvastatin tablet fell from 18.3 cents in November 2013 to 2.8 cents in October 2026. The year-by-year record, and the FDA approvals behind it.
What pharmacies paid for simvastatin, 2013 to 2026
Federal survey data put a generic 20 mg simvastatin tablet at 2.7 cents in November 2013 and 3.2 cents in October 2026. The year-by-year record, the 2023 jump and the approvals behind the market.
How to look up a drug on DailyMed
DailyMed is the National Library of Medicine's free archive of drug labels as companies submit them to FDA. How to search it by name or NDC, find inactive ingredients and imprints, and tell the leaflets apart.
What pharmacies pay for a month of common generics
Thirty tablets of each of the 10 most-used generics we track cost pharmacies $35.70 in January 2014 and $8.80 in October 2026. That is acquisition cost, and the rest of the price sits on top of it.
The long deflation of generic prices
Of 43 common generics in GxRadar's NADAC series, 35 cost pharmacies less in October 2026 than in January 2014. Federal data show how competition drives that decline, and the rarer spikes.
FDA's product-specific guidances, the study plans behind each generic
FDA has published 2,447 product-specific guidances telling generic makers what studies it expects for a given drug. About 98 percent are still drafts. What they say, and why they matter most for complex products.